Propanc Biopharma (NASDAQ Uplisting)

Print
General Information
Business:

Note: This is NOT an IPO. This is a unit public offering that is a NASDAQ Uplisting from the OTC Pink Marketplace, where the stock trades under the symbol “PPCB”. Each unit consists  of one share of common stock and one warrant to buy one share of common stock.

(Incorporated in Delaware)

We are a development-stage healthcare company that is currently focused on developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancer. Utilizing our scientific and oncology consultants, we have developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Our lead product candidate, PRP, is a variation upon our novel formulation and involves pro-enzymes, the inactive precursors of enzymes.

Note: Net loss and revenue figures are for the fiscal year that ended June 30, 2024. 

(Note: Propanc Biopharma is offering 1.0 million units at a price range of $4.00 to $6.00 to raise $5.0 million, according to its S-1/A filing dated March 28, 2025. Each unit consists of one share of common stock and one warrant.)
Industry: Pharmaceuticals
Employees: 2
Founded: 2007
Contact Information
Address 302, 6 Butler Street Camberwell, VIC 3124 Australia
Phone Number +61 03 9882 0780
Web Address https://www.propanc.com/
View Prospectus: Propanc Biopharma (NASDAQ Uplisting)
Financial Information
Market Cap $65.56mil
Revenues $0 mil (last 12 months)
Net Income $-2.01 mil (last 12 months)
IPO Profile
Symbol PPCB
Exchange NASDAQ
Shares (millions): 1.0
Price range $4.00 - $6.00
Est. $ Volume $5.0 mil
Manager / Joint Managers D. Boral Capital (ex-EF Hutton)/Craft Capital
CO-Managers
Expected To Trade:
Status: TBA
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change